| Tag |
First Indicator |
Second Indicator |
Subfields |
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
in00005739421 |
| 005 |
20260326163925.1 |
| 006 |
m o d |
| 007 |
cr cn||||||||| |
| 008 |
100225s2010 ne af ob 001 0 eng d |
| 040 |
|
|
|a OPELS
|b eng
|e pn
|c OPELS
|d CDX
|d OCLCQ
|d OPELS
|d OCLCF
|d CHVBK
|d OCLCO
|d DEBSZ
|d OCLCQ
|d ZZAND
|d OCLCO
|d OCLCQ
|d CASUM
|d OCLCO
|d OCLCA
|d D6H
|d AU@
|d OCLCO
|d WYU
|d OCLCO
|d OCLCA
|d OCLCQ
|d LEAUB
|d OCLCO
|d OCLCA
|d S2H
|d OCLCO
|d LVT
|d INARC
|d OCLCO
|d OCLCQ
|d OCLCO
|d OCLCL
|
| 019 |
|
|
|a 916414160
|a 1229177408
|
| 020 |
|
|
|a 9780123748959
|q (electronic bk.)
|
| 020 |
|
|
|a 012374895X
|q (electronic bk.)
|
| 020 |
|
|
|a 9780080953885
|q (online)
|
| 020 |
|
|
|a 0080953883
|
| 035 |
|
|
|a (OCoLC)528610703
|z (OCoLC)916414160
|z (OCoLC)1229177408
|
| 037 |
|
|
|a 175782:172203
|b Elsevier Science & Technology
|n http://www.sciencedirect.com
|
| 050 |
|
4 |
|a RD675
|b .B66 2010
|
| 060 |
|
4 |
|a 2009 K-642
|
| 060 |
|
4 |
|a WE 258
|b B71044 2010
|
| 082 |
0 |
4 |
|a 616.99471
|2 22
|
| 049 |
|
|
|a TXAM
|
| 245 |
0 |
0 |
|a Bone cancer :
|b progression and therapeutic approaches /
|c edited by Dominique Heymann.
|
| 250 |
|
|
|a 1st ed.
|
| 260 |
|
|
|a Amsterdam ;
|a Boston ;
|a London :
|b Academic,
|c ©2010.
|
| 300 |
|
|
|a 1 online resource (xv, 472 pages, 10 unnumbered pages of plates)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 520 |
|
|
|a The epidemiological and clinical importance of bone metastasis has long been recognized, but the past decade has seen an explosion in the fields of bone biology and bone cancer research. This period of time has been marked by a number of key discoveries that have led to the opening up of entirely new areas for investigation as well as new therapies which combine surgery and biological therapeutic approaches. Bone is a common site of cancer metastases - cancer cells commonly develop in bone and spread to other organ systems through the bloodstream. For example, the incidence of bone metastases in breast and prostate cancers is 70%, whereas it is only 30 to 40% in metastatic lung cancer. In clinical terms, bone metastases have substantial negative effects on a patient's quality of life and are a main cause of patient mortality. Given the global prevalence of breast and prostate cancers, knowledge of bone biology has become essential for the medical and cancer research communities. This book provides, all in one resource, the most recent data on bone cancer development (cellular and molecular mechanisms), genomic and proteomic analyses, clinical analyses (histopathology, imaging, pain monitoring), as well as new therapeutic approaches and clinical trials for primary bone tumors and bone metastases. Feature Presents a comprehensive, translational source for all aspects of bone cancer in one reference work Bone cancer experts (from all areas of research and practice) take readers from the bench research (cellular and molecular mechanism), through genomic and proteomic analysis, all the way to clinical analysis (histopathology and imaging) and new therapeutic approaches. Clear presentation by bone biologists of the cellular and molecular mechanisms underlying bone tumors and bone cancer metastasis as well as the genomic and proteomic assays used in detecting cancer within given organ systems Clear presentation by oncologists and radiologists of how histopathology, imaging, and pain monitoring can lead to new therapeutic approaches Benefit Saves researchers and clinicians time in quickly accessing the very latest details on a broad range of bone cancer issues, as opposed to searching through thousands of journal articles. Provides a common language for cancer researchers, bone biologists, oncologists, and radiologists to discuss bone tumors and how bone cancer metastases affects each major organ system Correct diagnosis (and therefore correct treatment) of cancer depends on a strong understanding of the molecular basis for the disease - both oncologists and radiologists will benefit Bone biologists will gain insight into how clinical observations and practices can feed back into the research cycle and will, therefore, be able to develop more targeted genomic and proteomic assays.
|
| 505 |
0 |
|
|a Section 1: Introduction -- Genetic control, frequencies and epidemiology of bone cancers -- The incidence and progression of metastatic bone lesions -- Section 2: Bone microenvironment and bone cancer -- Bone microenvironment and tumor growth -- Osteoblast Differentiation and Cell Signalling -- Osteoclast Differentiation and Function -- Cytokines in bone remodeling and bone tumors -- Proteases and bone tumors -- therapeutic approaches -- Section 3: Bone markers -- Early bone metastasis -- Bone remodeling markers and bone cancer -- Proteomic of bone cancers -- Genomic Alterations in Bone Tumors -- Biology of bone tumors and new diagnostic tools -- Gene profiling of osteosarcoma -- Molecular pathology of osteosarcoma -- Histopathology of prostate and breast metastases -- Technical aspects: how do we best prepare bone samples for proper histological analysis? -- Section 4: Myeloma, odontogenic tumors and bone metastases -- Multiple myeloma bone diseases -- Osteolytic lesions -- Bone metastases of prostatic cancer -- Bone metastases of breast cancer -- Section 5: Primary bone tumors -- Osteosarcoma and osteoblasts: diagnosis and therapy -- Ewing sarcoma family of tumors: diagnosis and therapy -- Non-surgical treatment of chondrosarcoma: diagnosis and therapy -- Chondrosarcoma of bone: diagnosis and therapy -- Osteoclast-rich lesions of bone: diagnosis and therapy -- Section 6: Imaging of bone cancers -- Interventional Radiologic Techniques -- Imaging of bone metastases -- Diagnosis of bone metastases -- Section 7: Pain control in bone cancers -- Pain control with radiotherapy -- Mechanisms and management of bone cancer pain -- Malignant skeletal pain -- Section 8: New therapeutic advances of bone cancers -- Primary bone tumors and novel therapeutic approaches -- Cytokine gene therapy in bone remodeling -- Bisphosphonates -- Multi-targeted approach -- RANKL and targeted therapy -- Apoptosis and drug resistance.
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
0 |
|
|a Print version record.
|
| 650 |
|
0 |
|a Bones
|x Cancer.
|
| 650 |
|
0 |
|a Bones
|x Cancer
|x Treatment.
|
| 650 |
|
2 |
|a Bone Neoplasms
|
| 650 |
|
2 |
|a Bone Neoplasms
|x therapy
|
| 650 |
|
6 |
|a Os
|x Cancer.
|
| 650 |
|
6 |
|a Os
|x Cancer
|x Traitement.
|
| 650 |
|
7 |
|a Bones
|x Cancer
|2 fast
|
| 650 |
|
7 |
|a Bones
|x Cancer
|x Treatment
|2 fast
|
| 650 |
|
7 |
|a Online-Ressource
|2 gnd
|
| 655 |
|
7 |
|a Electronic books.
|2 local
|
| 655 |
|
4 |
|a Internet Resources.
|
| 700 |
1 |
|
|a Heymann, Dominique.
|
| 710 |
2 |
|
|a ScienceDirect (Online service)
|
| 758 |
|
|
|i has work:
|a Bone cancer (Text)
|1 https://id.oclc.org/worldcat/entity/E39PCGGpkpk8HgrmCVWygVJkpd
|4 https://id.oclc.org/worldcat/ontology/hasWork
|
| 776 |
0 |
8 |
|i Print version:
|t Bone cancer.
|b 1st ed.
|d Amsterdam ; Boston ; London : Academic, ©2010
|z 9780123748959
|z 012374895X
|w (OCoLC)318877752
|
| 856 |
4 |
0 |
|u http://proxy.library.tamu.edu/login?url=https://www.sciencedirect.com/science/book/9780123748959
|z Connect to the full text of this electronic book
|t 0
|
| 955 |
|
|
|a Elsevier ScienceDirect 2026-2027
|
| 994 |
|
|
|a 92
|b TXA
|
| 999 |
f |
f |
|i 32c9ff10-c5dc-40ae-91c5-7df9b71be904
|s 23cb1765-1e14-48b5-8a9e-8e8f713d35d5
|t 0
|
| 952 |
f |
f |
|a Texas A&M University
|b College Station
|c Electronic Resources
|s www_evans
|d Available Online
|t 0
|e RD675 .B66 2010
|h Library of Congress classification
|
| 998 |
f |
f |
|a RD675 .B66 2010
|t 0
|l Available Online
|